cas 220812-09-9|| where to buy (3S,4R)-3-amino-4-hydroxy-pyrrolidin-2-one

Nom du produit:(3S,4R)-3-amino-4-hydroxy-pyrrolidin-2-one

IUPAC Name:(3S,4R)-3-amino-4-hydroxypyrrolidin-2-one

Unité d'emballage	Stock disponible	Prix($)
CM1018618-100mg	in stock	ȅŞƃ
CM1018618-250mg	in stock	ŪȖƴ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 220812-09-9 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:220812-09-9; Formule moléculaire:C4H8N2O2; Point de fusion:-; Code SMILES:N[C@@H]1C(=O)NC[C@H]1O; Densité:

: Numéro de catalogue:CM1018618; Poids moléculaire:116.12; Point d'ébullition:; N° Mdl:; Stockage:

: Pyrrolidines; Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

: VX-147; Vertex Pharmaceuticals announced that inaxaplin (VX-147) , a first-in-class molecule has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care. The clinical trial is designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with proteinuric kidney disease mediated by two variants in the APOL1 gene, known as AMKD. In addition, the trial has been expanded to include adolescents with AMKD ages 10 to 17 years.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.